AbVitro

Boston, United States Founded: 2012 • Age: 14 yrs Acquired By Juno Therapeutics
Therapeutic targets and antibodies are identified via immune sequencing technology.
Request Access

About AbVitro

AbVitro is a company based in Boston (United States) founded in 2012 was acquired by Juno Therapeutics in January 2016.. AbVitro has raised $1.87 million across 2 funding rounds from investors including Juno Therapeutics and Sante Ventures. The company has 17 employees as of December 31, 2015. AbVitro operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.

  • Headquarter Boston, United States
  • Employees 17 as on 31 Dec, 2015
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.87 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.87 M (USD), Series A

    Jun 02, 2013

  • Investors
  • Employee Count
    17

    as on Dec 31, 2015

  • Acquired by
    Juno Therapeutics

    (Jan 11, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of AbVitro

AbVitro has successfully raised a total of $1.87M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1.87 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $1.9M
  • First Round
  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2013 Amount Series A - AbVitro Valuation

investors

Apr, 2012 Amount Series A - AbVitro Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in AbVitro

AbVitro has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Juno Therapeutics and Sante Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Founded Year Domain Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by AbVitro

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - AbVitro

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Abvitro Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of AbVitro

AbVitro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
RNA-editing technologies are provided for precision medicine applications.
domain founded_year HQ Location
Dental implants and regenerative dentistry products are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Abvitro

Frequently Asked Questions about AbVitro

When was AbVitro founded?

AbVitro was founded in 2012.

Where is AbVitro located?

AbVitro is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is AbVitro a funded company?

AbVitro is a funded company, having raised a total of $1.87M across 2 funding rounds to date.

How many employees does AbVitro have?

As of Dec 31, 2015, the latest employee count at AbVitro is 17.

What does AbVitro do?

Founded in 2012 and based in Boston, United States, AbVitro operates in the biotechnology sector focused on therapeutic target discovery. A platform is utilized to leverage natural immune responses for addressing unmet medical needs in cancer, autoimmune, and infectious diseases. High-throughput single-cell sequencing is applied to identify natively paired B cell antibodies and T cell receptors from millions of cells.

Who are the top competitors of AbVitro?

AbVitro's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are AbVitro's investors?

AbVitro has 2 investors. Key investors include Juno Therapeutics, and Sante Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available